Actively Recruiting
Study of LY4050784, a Selective SMARCA2BRM Inhibitor, in Adults With Advanced Solid Tumors Having SMARCA4BRG1 Alterations
Led by Eli Lilly and Company · Updated on 2026-11-04
340
Participants Needed
32
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating LY4050784, a selective SMARCA2BRM inhibitor, in adults with advanced or metastatic solid tumors that have alterations in the SMARCA4 BRG1 gene. This includes patients who have previously received or are not candidates for standard treatments, or for whom no standard therapy exists. The study is conducted in two phases phase Ia focuses on dose escalation, and phase Ib on dose optimization and dose expansion, lasting up to about four years. Participants receive oral doses of LY4050784 alone or combined with other anticancer drugs such as pembrolizumab, pemetrexed, cisplatin, carboplatin, paclitaxel, or nab-paclitaxel. Treatments are given in 21-day cycles, and participants may continue treatment until criteria for stopping are met. The study compares different doses during phase Ia and assesses safety and efficacy during phase Ib, including both monotherapy and combination therapy groups. Throughout the study, participants undergo regular assessments to monitor safety, side effects, and antitumor activity, including response rates and disease control. Researchers also measure drug levels in the body and other pharmacokinetic properties. The safety and tolerability of LY4050784 alone and in combination are evaluated over approximately four years, with ongoing monitoring of adverse events and tumor response.
CONDITIONS
Brief Title
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here